Addex enters into at-the-market ads offering agreement with h.c. wainwright & co. llc.

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, january 31, 2024 – addex therapeutics (six: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an at the market offering agreement (the “atm agreement”) with h.c.
ADXN Ratings Summary
ADXN Quant Ranking